依库珠单抗治疗SLE和APS继发性TMA的病例系列与文献综述
本文报告迄今最大病例系列,9例SLE和/或APS相关难治性继发性TMA患者接受依库珠单抗治疗,4周时多数患者血小板、触珠蛋白、LDH、eGFR及蛋白尿等指标显著改善,提示依库珠单抗可能为标准化疗失败的重症患者提供治疗选择。
要点
- 4周时78%患者血小板计数改善≥75%。
- 2/3患者触珠蛋白和LDH改善>75%,半数eGFR改善25%。
- 3例需血透者中2例脱离透析,支持依库珠单抗用于难治性病例。
核心结论
- 依库珠单抗可能是SLE和/或APS相关继发性TMA且标准治疗失败的重症患者的潜在治疗选择。
研究设计与样本
- 病例系列纳入9例SLE和/或APS相关难治性继发性TMA患者,并附文献综述。
主要发现
- 4周时78%患者血小板计数改善75%。
- 4周时2/3患者触珠蛋白和LDH改善>75%。
- 4周时半数患者eGFR改善25%,43%患者蛋白尿减少。
- 3例需血透患者中2例脱离血透。
临床怎么用
- 对SLE和/或APS相关继发性TMA且标准治疗失败的重症患者,可考虑依库珠单抗治疗。
局限性
- 证据仅基于病例系列和专家意见,需集体努力明确依库珠单抗的作用和最佳时机。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Thrombotic microangiopathy (TMA) is a life-threatening, albeit infrequent, complication of systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS). Recommendations for the treatment of SLE- and APS-related secondary TMA are currently based solely on case reports and expert opinion. Unfortunately, interventions may not yield timely results or effectively halt the progression of TMA. Since complement activation plays a key role in the pathogenesis of secondary TMA due to SLE, APS, a therapy that targets the complement pathway is an attractive intervention. Eculizumab, a recombinant, fully humanized IgG2/IgG4 monoclonal antibody inhibits C5 activation and is FDA-approved for PNH and atypical HUS (aHUS). However, limited case reports are available on its use in treatment of secondary TMA. CASE PRESENTATION AND RESULTS: We present the largest case series to date that includes 9 patients with SLE and/or APS who were successfully treated with eculizumab for refractory secondary TMA. In this case series, we report significant responses in hematology values, renal function and other organs following treatment with eculizumab. At 4 weeks, 75% improvement in platelet counts was observed in 78% of patients. Two-thirds of patients demonstrated >75% improvement of haptoglobin and LDH at four weeks. At 4 weeks, eGFR improved by 25% in half of the patients, and 43% had reductions in proteinuria. Two of 3 patients that required hemodialysis were able to be taken off hemodialysis. CONCLUSION: Based on these observations, we suggest that eculizumab may be a potential treatment option for acutely ill patients with secondary TMA due to SLE and/or APS who have failed standard of care. A collective approach is needed to better elucidate the role and optimal timing of eculizumab use in the management of TMA complicating SLE and/or APS.
引用
- Kello N, Khoury LE, Marder G, et al. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature. Semin Arthritis Rheum. 2018. PMID: 30598332. doi:10.1016/j.semarthrit.2018.11.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。